Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Agnieszka Porowska
First‐line R‐CVP Versus R‐CHOP Induction Immunochemotherapy for Indolent Lymphoma With Rituximab Maintenance. A Multicentre, Phase III Randomized Study by the Polish Lymphoma Research Group PLRG4
British Journal of Haematology
Hematology
Related publications
Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Rituximab Maintenance for Patients With Diffuse Large B-Cell Lymphoma in First Complete Remission: Results From a Randomized Hovon-Nordic Lymphoma Group Phase Iii Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Prospective Clinical Study of R-CMD Therapy for Indolent B Cell Lymphoma and Mantle Cell Lymphoma From the Hokuriku Hematology Oncology Study Group
Medical Oncology
Medicine
Cancer Research
Oncology
Hematology